Molecular Mechanisms and Clinical Applications of Angiogenesis

Overview

Journal Nature

Specialty Science

Date 2011 May 20

PMID 21593862

Citations 2344

Authors

Peter Carmeliet

Rakesh K Jain

Affiliations

Soon will be listed here.

Abstract

Blood vessels deliver oxygen and nutrients to every part of the body, but also nourish diseases such as cancer. Over the past decade, our understanding of the molecular mechanisms of angiogenesis (blood vessel growth) has increased at an explosive rate and has led to the approval of anti-angiogenic drugs for cancer and eye diseases. So far, hundreds of thousands of patients have benefited from blockers of the angiogenic protein vascular endothelial growth factor, but limited efficacy and resistance remain outstanding problems. Recent preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.

Citing Articles

Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance.

Xiao Y, Hassani M, Moghaddam M, Fazilat A, Ojarudi M, Valilo M Med Oncol. 2025; 42(4):108.

PMID: 40087196 DOI: 10.1007/s12032-025-02675-8.

CT-based radiomics-deep learning model predicts occult lymph node metastasis in early-stage lung adenocarcinoma patients: A multicenter study.

Yin X, Lu Y, Cui Y, Zhou Z, Wen J, Huang Z Chin J Cancer Res. 2025; 37(1):12-27.

PMID: 40078558 PMC: 11893343. DOI: 10.21147/j.issn.1000-9604.2025.01.02.

Anti-Angiogenic Potential of Marine -Derived Lucknolide A on VEGF/VEGFR2 Signaling in Human Endothelial Cells.

Choi B, Jo M, Shin H, Park S Molecules. 2025; 30(5).

PMID: 40076212 PMC: 11901821. DOI: 10.3390/molecules30050987.

The molecular mechanism of ginsenoside Rh2 and its octyl ester derivative on anti-angiogenesis in cancer treatment: The battle between PI3K and ROS.

Hu Q, Zhong X, Feng H, Li X, Zhang Z, Pan Y J Ginseng Res. 2025; 49(2):208-222.

PMID: 40061477 PMC: 11889380. DOI: 10.1016/j.jgr.2025.01.002.

Vascularised organoids: Recent advances and applications in cancer research.

Zhou R, Brislinger D, Fuchs J, Lyons A, Langthaler S, Hauser C Clin Transl Med. 2025; 15(3):e70258.

PMID: 40045486 PMC: 11882480. DOI: 10.1002/ctm2.70258.

References

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

Swift M, Weinstein B . Arterial-venous specification during development. Circ Res. 2009; 104(5):576-88. DOI: 10.1161/CIRCRESAHA.108.188805. View

Blasi F, Carmeliet P . uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002; 3(12):932-43. DOI: 10.1038/nrm977. View

Adams R, Eichmann A . Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol. 2010; 2(5):a001875. PMC: 2857165. DOI: 10.1101/cshperspect.a001875. View

Jakobsson L, Franco C, Bentley K, Collins R, Ponsioen B, Aspalter I . Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol. 2010; 12(10):943-53. DOI: 10.1038/ncb2103. View

de Palma M, Venneri M, Galli R, Sergi Sergi L, Politi L, Sampaolesi M . Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8(3):211-26. DOI: 10.1016/j.ccr.2005.08.002. View

Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D . Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111(9):1287-95. PMC: 154450. DOI: 10.1172/JCI17929. View

Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C . Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 2010; 16(4):420-8. DOI: 10.1038/nm.2131. View

Thurston G, Noguera-Troise I, Yancopoulos G . The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer. 2007; 7(5):327-31. DOI: 10.1038/nrc2130. View

10.

Yan M, Callahan C, Beyer J, Allamneni K, Zhang G, Ridgway J . Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010; 463(7282):E6-7. DOI: 10.1038/nature08751. View

11.

Gerhardt H, Semb H . Pericytes: gatekeepers in tumour cell metastasis?. J Mol Med (Berl). 2007; 86(2):135-44. DOI: 10.1007/s00109-007-0258-2. View

12.

Duda D, Kozin S, Kirkpatrick N, Xu L, Fukumura D, Jain R . CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. Clin Cancer Res. 2011; 17(8):2074-80. PMC: 3079023. DOI: 10.1158/1078-0432.CCR-10-2636. View

13.

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

14.

Buysschaert I, Schmidt T, Roncal C, Carmeliet P, Lambrechts D . Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. J Cell Mol Med. 2009; 12(6B):2533-51. PMC: 3828872. DOI: 10.1111/j.1582-4934.2008.00515.x. View

15.

Lichtenberger B, Tan P, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M . Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 2010; 140(2):268-79. DOI: 10.1016/j.cell.2009.12.046. View

16.

Bergers G, Brekken R, McMahon G, Vu T, Itoh T, Tamaki K . Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2(10):737-44. PMC: 2852586. DOI: 10.1038/35036374. View

17.

Nagy J, Dvorak A, Dvorak H . VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007; 2:251-75. DOI: 10.1146/annurev.pathol.2.010506.134925. View

18.

Tvorogov D, Anisimov A, Zheng W, Leppanen V, Tammela T, Laurinavicius S . Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell. 2010; 18(6):630-40. DOI: 10.1016/j.ccr.2010.11.001. View

19.

Beenken A, Mohammadi M . The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8(3):235-53. PMC: 3684054. DOI: 10.1038/nrd2792. View

20.

Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg J . Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008; 456(7223):814-8. PMC: 3103772. DOI: 10.1038/nature07445. View